127 related articles for article (PubMed ID: 3928575)
1. In-vitro and in-vivo activities of a novel cephamycin MT-141 against the Bacteroides fragilis group in comparison with six cephem antibiotics.
Kasai T; Hara T; Tamura A; Kazuno Y; Inouye S; Goto S; Kuwahara S
J Antimicrob Chemother; 1985 Jun; 15(6):701-14. PubMed ID: 3928575
[TBL] [Abstract][Full Text] [Related]
2. [In vitro and in vivo antimicrobial activities of cefmetazole against Bacteroides fragilis].
Isono M; Kawashima K; Yamada N; Aoki M; Kobayashi T; Sawa K; Watanabe K; Ueno K
Jpn J Antibiot; 1982 Jul; 35(7):1667-72. PubMed ID: 6757469
[TBL] [Abstract][Full Text] [Related]
3. beta-Lactamase produced by a highly beta-lactam-resistant strain of Bacteroides fragilis: an obstacle to the chemotherapy of experimental mixed infections.
Ajiki Y; Koga T; Ohya S; Takenouchi T; Yasuda H; Watanabe K; Ueno K
J Antimicrob Chemother; 1991 Oct; 28(4):537-46. PubMed ID: 1761449
[TBL] [Abstract][Full Text] [Related]
4. Cephamycin inactivation due to enzymatic hydrolysis by beta-lactamase from Bacteroides fragilis.
Yotsuji A; Minami S; Kakizawa H; Yasuda T; Takai A; Saikawa I; Inoue M; Mitsuhashi S
Antimicrob Agents Chemother; 1985 Dec; 28(6):773-7. PubMed ID: 3878690
[TBL] [Abstract][Full Text] [Related]
5. Comparative antibacterial activities of 7 alpha-methoxy cephalosporins and 7 beta-methoxyiminoacetamido cephalosporins against Bacteroides fragilis.
Kesado T; Watanabe K; Asahi Y; Isono M; Ueno K
Antimicrob Agents Chemother; 1984 Jan; 25(1):131-3. PubMed ID: 6322676
[TBL] [Abstract][Full Text] [Related]
6. Antibacterial activity of the cephamycin cefotetan: an in-vitro comparison with other beta-lactam antibiotics.
Clarke AM; Zemcov SJ
J Antimicrob Chemother; 1983 Jan; 11 Suppl():67-72. PubMed ID: 6404881
[TBL] [Abstract][Full Text] [Related]
7. Susceptibility patterns and characterization of beta-lactamases in clinical isolates of Bacteroides fragilis.
Mastrantonio P; Spigaglia P; Sebastianelli A
Eur J Clin Microbiol Infect Dis; 1994 Jun; 13(6):475-80. PubMed ID: 7957267
[TBL] [Abstract][Full Text] [Related]
8. [Antibacterial activity of MT-141 against anaerobic bacteria].
Watanabe T; Hara T; Kasai T; Ishii T; Miyauchi K; Date H; Jinzaki M; Shindo H; Matsugami A; Goi H
Jpn J Antibiot; 1984 Jun; 37(6):1058-69. PubMed ID: 6092738
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo antibacterial activity of T-1982, a new semisynthetic cephamycin antibiotic.
Tai M; Fukuoka Y; Yotsuji A; Kumano K; Takahata M; Mikami H; Yasuda T; Saikawa I; Mitsuhashi S
Antimicrob Agents Chemother; 1982 Nov; 22(5):728-34. PubMed ID: 6983861
[TBL] [Abstract][Full Text] [Related]
10. Enzyme-mediated resistance of Bacteroides fragilis to moxalactam.
Maskell JP; Nasu M
Lancet; 1981 Mar; 1(8222):733. PubMed ID: 6110951
[No Abstract] [Full Text] [Related]
11. In-vitro sensitivity tests and in-vivo efficacy of cephalosporins against Bacteroides fragilis.
Brook I
J Antimicrob Chemother; 1990 Jul; 26(1):158-61. PubMed ID: 2211440
[No Abstract] [Full Text] [Related]
12. Beta-lactamases from Bacteroides fragilis active against oximino-cephalosporins.
Werner RG; Appel KR; Erne AM
Arzneimittelforschung; 1985; 35(1A):348-50. PubMed ID: 3872669
[TBL] [Abstract][Full Text] [Related]
13. Antibacteroides and beta-lactamase inhibitory activities of moxalactam.
Fu KP; Neu HC
J Antimicrob Chemother; 1981 Oct; 8(4):337-41. PubMed ID: 6271727
[No Abstract] [Full Text] [Related]
14. In vitro and in vivo antibacterial activities of MT-141, a new semisynthetic cephamycin, compared with those of five cephalosporins.
Inouye S; Goi H; Watanabe T; Hara T; Miyauchi K; Yoshida T; Kazuno Y; Kadosawa H; Hirano F; Kawaharajo K
Antimicrob Agents Chemother; 1984 Nov; 26(5):722-9. PubMed ID: 6440478
[TBL] [Abstract][Full Text] [Related]
15. In vitro susceptibility vs. in vivo efficacy of various antimicrobial agents against the Bacteroides fragilis group.
Brook I
Rev Infect Dis; 1991; 13(6):1170-80. PubMed ID: 1775850
[TBL] [Abstract][Full Text] [Related]
16. Inactivation of cefuroxime and cefotaxime by Bacteroides fragilis in vitro, and its influence on the treatment of an experimental Escherichia coli/Bacteroides fragilis mixed infection.
Beale AS; Gisby J
J Antimicrob Chemother; 1989 Jul; 24(1):29-37. PubMed ID: 2674099
[TBL] [Abstract][Full Text] [Related]
17. Comparative susceptibility of cefminox and cefoxitin to beta-lactamases of Bacteroides spp.
Soriano F; Edwards R; Greenwood D
J Antimicrob Chemother; 1991 Jul; 28(1):55-60. PubMed ID: 1769943
[TBL] [Abstract][Full Text] [Related]
18. Cefotetan: in-vitro antibacterial activity and susceptibility to beta-lactamases.
Phillips I; King A; Shannon K; Warren C
J Antimicrob Chemother; 1983 Jan; 11 Suppl():1-9. PubMed ID: 6601650
[TBL] [Abstract][Full Text] [Related]
19. Cefmetazole: a broad spectrum cephem antibiotic effective on methicillin- and cephem-resistant Staphylococcus aureus.
Yokota T; Yoshida R; Utsui Y; Tajima M
Drugs Exp Clin Res; 1985; 11(1):29-38. PubMed ID: 3915273
[TBL] [Abstract][Full Text] [Related]
20. Cephalosporin-resistance in the Bacteroides fragilis group and the effect of clavulanic acid.
Maskell JP; Nasu M; Williams JD
J Antimicrob Chemother; 1984 Jan; 13(1):23-30. PubMed ID: 6607916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
